AKOUSTIS TECHNOLOGIES INC(AKTSQ.US)

Company Encyclopedia

AKOUSTIS TECHNOLOGIES INC

AKTSQ.US

422.59 B

AKTSQ.USMarket value -Rank by Market Cap -/-

Financial Score

23/01/2026 Update

Electronic ComponentsIndustry

Industry Ranking0/27

Industry medianC

Industry averageC

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreE
- ROE-11970.59%E
- Profit Margin-524.47%E
- Gross Margin47.66%B
Growth ScoreD
- Revenue YoY2.98%C
- Net Profit YoY-138.78%E
- Total Assets YoY-54.88%E
- Net Assets YoY-196.20%E
Cash ScoreC
- Cash Flow Margin-19.07%D
- OCF YoY2.98%C
Operating ScoreD
- Turnover0.32D
Debt ScoreE
- Gearing Ratio213.67%E

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

The IPO Buzz: Aktis Oncology (AKTS) Prices IPO at $18 – Top of Range – 1st Big IPO of 2026

Aktis Oncology (AKTS) has priced its IPO at $18, the top of its range, raising $317.7 million by selling 17.65 million shares. The stock will begin trading on NASDAQ on January 9, 2026. Eli Lilly has shown interest in purchasing $100 million of stock in the IPO. Aktis plans to use the proceeds for clinical trials of its drug candidates targeting advanced bladder cancer and solid tumors. The company reported a net loss of $60.65 million on revenue of $5.56 million for the year ending September 30, 2025.

IPO Scoop·01/09/2026 10:42

AKTSQ

0.00%

IPO Scoop·01/09/2026 10:42

AKTSQ

0.00%